J Kotzerke1. 1. Technische Universität Dresden, Universitätsklinikum Carl Gustav Carus, Fetscherstr. 74, 01307, Dresden, Deutschland, joerg.kotzerke@mailbox.tu-dresden.de.
Abstract
BACKGROUND: Diagnostic imaging with positron emission tomography (PET) is becoming increasingly more involved in oncological therapy management. OBJECTIVES: How can PET be helpful in oncological surgery? METHODS: After a short introduction into the basic principles of PET the current state of imaging as well as indications and limitations of the method are described. RESULTS: The PET is a functional and quantitative imaging technique, enabling detection and characterization of tumors. It is applied in pretherapeutic staging as well as in follow-up and therapy assessment. The use of PET changes the therapy management in about one third of all oncology patients. New radiopharmaceuticals and novel technologies expand the diagnostic potential. DISCUSSION: Hybrid imaging with PET computed tomography (CT) and PET magnetic resonance imaging (MRI) further improves diagnostic imaging and increases the acceptance of PET further.
BACKGROUND: Diagnostic imaging with positron emission tomography (PET) is becoming increasingly more involved in oncological therapy management. OBJECTIVES: How can PET be helpful in oncological surgery? METHODS: After a short introduction into the basic principles of PET the current state of imaging as well as indications and limitations of the method are described. RESULTS: The PET is a functional and quantitative imaging technique, enabling detection and characterization of tumors. It is applied in pretherapeutic staging as well as in follow-up and therapy assessment. The use of PET changes the therapy management in about one third of all oncology patients. New radiopharmaceuticals and novel technologies expand the diagnostic potential. DISCUSSION: Hybrid imaging with PET computed tomography (CT) and PET magnetic resonance imaging (MRI) further improves diagnostic imaging and increases the acceptance of PET further.
Authors: Jan-Henning Schierz; Thomas Opfermann; Jörg Steenbeck; Eric Lopatta; Utz Settmacher; Andreas Stallmach; Robert J Marlowe; Martin Freesmeyer Journal: J Nucl Med Date: 2013-03-25 Impact factor: 10.057
Authors: F Hofheinz; C Pötzsch; L Oehme; B Beuthien-Baumann; J Steinbach; J Kotzerke; J van den Hoff Journal: Nuklearmedizin Date: 2011-10-26 Impact factor: 1.379
Authors: Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245